LUCAS WANGERIN: Open Payments
NPI 1487927257 · FORT CARSON, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$815 in 37 payments from 20 companies in 2025. Trend: 2023 $39 · 2024 $432 · 2025 $815
Food & beverage: $815
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $127 |
| Lilly USA, LLC | 7 | $125 |
| AstraZeneca Pharmaceuticals LP | 4 | $91 |
| Otsuka America Pharmaceutical, Inc. | 3 | $80 |
| Amgen Inc. | 2 | $48 |
| Medtronic, Inc. | 1 | $44 |
| ABBVIE INC. | 1 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $32 |
| Astellas Pharma US Inc | 1 | $25 |
| Edwards Lifesciences Corporation | 1 | $24 |
Products named: MOUNJARO, REXULTI, Ozempic, Rybelsus, SYMPLICITY G3, MAVYRET, FANAPT, KRYSTEXXA.
Industry payments across CO — which companies pay providers there.
